欢迎访问中国比较医学杂志编辑部网站！

设为首页 | 加入收藏

李延康,贺钢枫.Siglec-15 抗体在非小细胞肺癌中的调控机制研究[J].中国比较医学杂志,2023,33(1):144~148.

Siglec-15 抗体在非小细胞肺癌中的调控机制研究

Role of anti-Siglec-15 in non-small cell lung cancer

投稿时间：2022-06-21

DOI：10. 3969 / j.issn.1671-7856. 2023. 01. 019

中文关键词: 免疫检查点抑制剂唾液酸结合免疫球蛋白样凝集素-15 非小细胞肺癌

英文关键词:ICIs Siglec-15 NSCLC

基金项目:

作者	单位
李延康	包头市中心医院(内蒙古医科大学包头临床医学院)心胸外科,内蒙古包头 014000
贺钢枫	包头市中心医院(内蒙古医科大学包头临床医学院)心胸外科,内蒙古包头 014000

Author Name	Affiliation
LI Yankang	Baotou Central Hospital (the Baotou Affiliated Hospital of Inner Mongolia Medical University), Department of Cardiothoracic Surgery, Baotou 014000, China
HE Gangfeng	Baotou Central Hospital (the Baotou Affiliated Hospital of Inner Mongolia Medical University), Department of Cardiothoracic Surgery, Baotou 014000, China

摘要点击次数: 380

全文下载次数: 164

中文摘要:

唾液酸结合免疫球蛋白样凝集素-15( sialic acid-binding immunoglobulin-like lectin,Siglec-15)作为新发现的一种免疫检查点抑制剂(immune checkpoint inhibitors, ICIs),其广泛表达于多种肿瘤细胞,并与程序性死亡受体 1(programmed cell death 1, PD-1)和程序性死亡受体-配体 1(programmed cell death ligand 1, PD-L1)的表达互斥,可以作为一个新的 ICIs 治疗靶点,为 PD-1/ PD-L1 治疗无响应的患者提供另一种治疗选择。本文拟从 Siglec-15 的特征通路、参与免疫调节机制以及在肿瘤相关的表达等方面的近期研究成果综述。分析研究 Siglec-15 抗体的临床应用结果,探讨 Siglec-15 在非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗中的应用意义以及治疗前景。

英文摘要:

As a newly discovered ICI, Siglec-15 is widely expressed in various tumor cell types, and PD-1/ PD-L1 expressions is mutually exclusive. Siglec-15 may be a new therapeutic target for PD-1/ PD-L1 as a treatment option for patients who do not respond to therapy. This review discusses the recent research of the characteristic pathways of Siglec- 15, its involvement in immune regulation mechanisms, and its tumor-related expression. Clinical application of an anti- Siglec-15 antibody was analyzed, and the therapeutic prospect of Siglec-15 for NSCLC treatment is discussed.

查看全文查看/发表评论下载PDF阅读器

关闭